Allogene Therapeutics, Inc. (ALLO)

2.9200 +0.1600 (+5.80%) 收市：04:00PM EDT

Allogene Therapeutics, Inc.

210 East Grand Avenue
South San Francisco, CA 94080
United States
650 457 2700
https://www.allogene.com

版塊: Healthcare
行業: Biotechnology
全職員工: 232

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Arie S. Belldegrun F.A.C.S., M.D.	Co-Founder & Executive Chairman	649.1k	無	1949
Dr. David D. Chang M.D., Ph.D.	Co-Founder, President, CEO & Director	994.6k	無	1960
Mr. Joshua A. Kazam	Co-Founder & Director	260.5k	無	1977
Mr. Timothy L. Moore Ph.D.	Executive VP & Chief Technical Officer	554.35k	無	1961
Dr. Zachary J. Roberts M.D., Ph.D.	Executive VP of Research & Development and Chief Medical Officer	747.39k	無	1978
Mr. Geoffrey M. Parker	Executive VP & CFO	無	無	1965
Mr. Earl M. Douglas Esq.	Senior VP, General Counsel, Compliance Officer & Corporate Secretary	無	無	1963
Ms. Susan R. Lundeen	Chief People Officer	無	無	1966
Ms. Christine Cassiano	Executive VP, Chief Corporate Affairs & Brand Strategy Officer	無	無	無
Yinlin Chen	Senior Vice President of Finance	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

公司管治

截至 2024年4月29日 止，Allogene Therapeutics, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：2；董事會：9；股東權利：8；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。